Αυστραλία - Αγγλικά - APVMA (Australian Pesticides and Veterinary Medicines Authority)

croda surfactants (a division of croda australia p/l) - teric 12 a 23 - anti-bloat

Αυστραλία - Αγγλικά - APVMA (Australian Pesticides and Veterinary Medicines Authority)

croda surfactants (a division of croda australia p/l) - teric 12 a 12 - anti-bloat

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

procter & gamble pharmaceuticals - nitrofurantoin, macrocrystalline (unii: 927ah8112l) (nitrofurantoin - unii:927ah8112l) - capsule - 25 mg - macrodantin is specifically indicated for the treatment of urinary tract infections when due to susceptible strains of escherichia coli, enterococci, staphylococcus aureus , and certain susceptible strains of klebsiella and enterobacter species. nitrofurantoin is not indicated for the treatment of pyelonephritis or perinephric abscesses. to reduce the development of drug-resistant bacteria and maintain the effectiveness of macrodantin and other antibacterial drugs, macrodantin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. nitrofurantoins lack the broader tissue distribution of other therapeutic agents approved for urinary tract infections. consequently, many patient

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

almatica pharma llc - nitrofurantoin (unii: 927ah8112l) (nitrofurantoin - unii:927ah8112l) - nitrofurantoin 25 mg - macrodantin is specifically indicated for the treatment of urinary tract infections when due to susceptible strains of escherichia coli , enterococci, staphylococcus aureus , and certain susceptible strains of klebsiella and enterobacter species. nitrofurantoin is not indicated for the treatment of pyelonephritis or perinephric abscesses. to reduce the development of drug-resistant bacteria and maintain the effectiveness of macrodantin and other antibacterial drugs, macrodantin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. nitrofurantoins lack the broader tissue distribution of other therapeutic agents approved for urinary tract infections. consequently, many patients

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - nitrofurantoin, quantity: 100 mg - capsule, hard - excipient ingredients: maize starch; purified talc; lactose monohydrate; gelatin; quinoline yellow; titanium dioxide; sodium lauryl sulfate; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; ethanol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; simethicone - indications as at 1 january 1991 : treatment of urinary tract infections such as cystitis and pyelitis when due to susceptible pathogens. nitrofurantoin does not reach effective levels in plasma and consequently is not indicated for cortical or perinephric abscesses and in cases of prostatitis.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - nitrofurantoin, quantity: 50 mg - capsule, hard - excipient ingredients: gelatin; maize starch; quinoline yellow; titanium dioxide; lactose monohydrate; purified talc; sodium lauryl sulfate; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; ethanol; shellac; iron oxide black; simethicone; strong ammonia solution; potassium hydroxide - indications as at 1 january 1991 : treatment of urinary tract infections such as cystitis and pyelitis when due to susceptible pathogens. nitrofurantoin does not reach effective levels in plasma and consequently is not indicated for cortical or perinephric abscesses and in cases of prostatitis.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - nitrofurantoin -

Ιρλανδία - Αγγλικά - HPRA (Health Products Regulatory Authority)

mercury pharmaceuticals ltd - nitrofurantoin - capsule, hard - 100 milligram(s) - nitrofuran derivatives; nitrofurantoin

Ιρλανδία - Αγγλικά - HPRA (Health Products Regulatory Authority)

mercury pharmaceuticals ltd - nitrofurantoin - capsule, hard - 50 milligram(s) - nitrofuran derivatives; nitrofurantoin

Μάλτα - Αγγλικά - Medicines Authority

mercury pharmaceuticals limited - nitrofurantoin - hard capsule - nitrofurantoin 100 mg - antibacterials for systemic use